Gilead Sciences Inc. [NASDAQ: GILD] traded at a high on 01/10/22, posting a 1.16 gain after which it closed the day’ session at $72.09. The company report on January 10, 2022 that Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into two clinical trial collaboration and supply agreements with Merck (known as MSD outside of the United States and Canada) to evaluate the combination of Gilead’s Trop-2 targeting antibody-drug conjugate (ADC) Trodelvy® (sacituzumab govitecan-hziy) and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first-line metastatic non-small cell lung cancer (NSCLC). As part of the collaboration, Merck will sponsor a global Phase 3 clinical trial of Trodelvy in combination with KEYTRUDA as a first-line treatment for patients with metastatic NSCLC. Additionally, the companies recently established an agreement whereby Gilead will sponsor a Phase 2 signal-seeking study evaluating combinations that include pembrolizumab in first-line NSCLC.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
“We’re excited to broaden our clinical collaborations with Merck to investigate Trodelvy in combination with KEYTRUDA in another cancer where there is tremendous need for novel combinations to help improve patient outcomes,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “This partnership builds on our ambition of providing alternatives to traditional chemotherapy with Trodelvy containing regimens across some of the most difficult-to-treat cancers.”.
The results of the trading session contributed to over 10214120 shares changing hands. Over the past one week, the price volatility of Gilead Sciences Inc. stands at 1.34% while the volatility over the past one month is 1.53%.
The market cap for GILD stock reached $90.85 billion, with 1.26 billion shares outstanding and 1.25 billion shares in the current float. Compared to the average trading volume of 6.90M shares, GILD reached a trading volume of 10214120 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Gilead Sciences Inc. [GILD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $77.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on January 06, 2022. While these analysts kept the previous recommendation, Wells Fargo raised their target price to Equal Weight. The new note on the price target was released on December 09, 2021, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another raise to $80, while Goldman analysts kept a Neutral rating on GILD stock. On November 19, 2021, analysts increased their price target for GILD shares from 72 to 85.
The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.11, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.31. The Price to Book ratio for the last quarter was 4.22, with the Price to Cash per share for the same quarter was set at 4.55. Price to Free Cash Flow for GILD in the course of the last twelve months was 15.34 with Quick ratio for the last quarter at 1.20.
How has GILD stock performed recently?
Gilead Sciences Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.68. With this latest performance, GILD shares gained by 2.55% in over the last four-week period, additionally plugging by 6.00% over the last 6 months – not to mention a rise of 15.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 55.42, with the RSI for the last a single of trading hit 52.15, and the three-weeks RSI is set at 56.50 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 69.81, while it was recorded at 71.87 for the last single week of trading, and 68.70 for the last 200 days.
Gilead Sciences Inc. [GILD]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +42.38 and a Gross Margin at +81.70. Gilead Sciences Inc.’s Net Margin is presently recorded at +0.50.
Return on Total Capital for GILD is now 21.25, given the latest momentum, and Return on Invested Capital for the company is 0.27. Return on Equity for this stock inclined to 0.60, with Return on Assets sitting at 0.19. When it comes to the capital structure of this company, Gilead Sciences Inc. [GILD] has a Total Debt to Total Equity ratio set at 176.45. Additionally, GILD Total Debt to Total Capital is recorded at 63.83, with Total Debt to Total Assets ending up at 46.95. Long-Term Debt to Equity for the company is recorded at 160.71, with the Long-Term Debt to Total Capital now at 58.14.
Reflecting on the efficiency of the workforce at the company, Gilead Sciences Inc. [GILD] managed to generate an average of $9,044 per employee. Receivables Turnover for the company is 5.81 with a Total Asset Turnover recorded at a value of 0.38.Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.40.
Earnings analysis for Gilead Sciences Inc. [GILD]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to 1.32%.
Insider trade positions for Gilead Sciences Inc. [GILD]
There are presently around $72,181 million, or 82.50% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 120,982,349, which is approximately -2.28% of the company’s market cap and around 0.10% of the total institutional ownership; CAPITAL RESEARCH GLOBAL INVESTORS, holding 114,548,108 shares of the stock with an approximate value of $8.26 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $7.58 billion in GILD stock with ownership of nearly 0.178% of the company’s market capitalization.
Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 731 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 59,144,579 shares. Additionally, 678 investors decreased positions by around 41,756,989 shares, while 231 investors held positions by with 900,357,558 shares. The mentioned changes placed institutional holdings at 1,001,259,126 shares, according to the latest SEC report filing. GILD stock had 122 new institutional investments in for a total of 7,966,098 shares, while 87 institutional investors sold positions of 2,305,222 shares during the same period.